Human medicinal products

Pharmaceutical Market Access


We manage the pricing and reimbursement of human medicinal products, from market entry through to the annual pricing periods, in a way that is compliant and commercially sound.

Scope of service

Our scope of services

01

Pricing

  • Preparation and follow-up of TİTCK price applications (initial price, price change, actual source price change period)
  • Reference country price research; actual source price and benchmark source price calculations
  • Applications for price-protected products, below-threshold products and cost-card pricing
  • Analysis and reporting of the impact of the fixed euro rate and regulatory changes (Decree, Communiqué, Guideline) on the product portfolio
02

Reimbursement

  • Preparation of SGK reimbursement application dossiers; follow-up of TEDK and Medicines Reimbursement Commission procedures
  • Calculation of the impact of the SGK institutional discount and generic entries on price and discount
  • Monitoring of SUT amendments and assessment of their impact on products
  • Applications under the SGK Dynamic Procurement System (DAS) for medicines supplied from abroad
  • Support for alternative reimbursement and pharmacoeconomic evaluation dossiers
03

Market Access Strategy

  • Pricing and reimbursement scenarios and revenue projections ahead of product launch

Frequently asked questions

Common questions

Answers are based on Presidential Decree No. 11031 of 11/3/2026 and the Communiqué on the Pricing of Medicinal Products for Human Use of 29.08.2026 and on TİTCK’s İFPAS Company Application User Guide (Version 4, 2026), and are for general information only. Current legislation and Agency announcements prevail.

How are medicine prices set in Türkiye?

Pricing follows Presidential Decree No. 11031 of 11/3/2026 and the Communiqué on the Pricing of Medicinal Products for Human Use, which entered into force on 29 August 2026. A Source Price in euros is set based on the product’s ex-factory price in the source countries. The company selling price may be set up to the Turkish lira equivalent of this Source Price. Wholesaler and pharmacist margins are then added according to the price bands in the Decree. Details of the implementation are set out in TİTCK’s Guideline on the Pricing of Medicinal Products for Human Use (EDİT-KLVZ-11; last revised 20 October 2026).

Which are the source countries?

France, Spain, Italy, Portugal and Greece. For imported products, the batch release countries listed in the marketing authorisation and the country of shipment on the control certificate also count as source countries. If no price is found there, the lowest ex-factory price in EU countries is used, followed by the lowest price in the countries published by the Ministry.

What do Actual Source Price, Benchmark Source Price and Source Price mean?

The Actual Source Price is the ex-factory price, excluding VAT and discounts, of the product while it is authorised and marketed in the source countries. The Benchmark Source Price (mihenk kaynak fiyat) is the Actual Source Price in euros recorded in the Ministry’s database and used as the basis for calculations. The Source Price is the euro price obtained by applying a ratio such as 100%, 80% or 60% to the Benchmark Source Price. The company selling price may be set up to the Turkish lira equivalent of the Source Price at the periodic euro value.

What is a price-protected product, and what changed with the new Communiqué?

Products containing an active substance, any pharmaceutical form of which was first marketed anywhere in the world before 1/1/2000, are price-protected. Under the previous Communiqué the cut-off date was 1/8/1987. A combination is not price-protected if any of its active substances is not. As a rule, the Source Price of price-protected products is 80% of the Benchmark Source Price. The new date applies from the effective date announced at the end of the 2026 Actual Source Price change period. Reference products that become price-protected through this change and have no generic on the market have their Source Price reduced to 80%, while their current company selling price is retained and reviewed at the next Commission meeting.

How are generics priced, and what is the new rule for the first generic?

For products that are not price-protected, once a generic is on the market the Source Price of both the reference product and its generics is 60% of the Benchmark Source Price. Under the new Communiqué, for products above the threshold set in the Decree, this ratio is applied in stages from the launch of the first generic: 80% in the first year, 75% in the second and 70% in the third. If domestically manufactured generics reach a 5% market share by the end of the first year, 80% also applies in the second year; if they reach 10% by the end of the second year, 75% applies in the third. The rule applies to first generics launched after 13/3/2026 and their equivalent packs and strengths.

How are products without an Actual Source Price priced?

Domestically manufactured reference and generic products whose price cannot be found in the source countries are priced using a cost card. The cost card is prepared and approved by the applicant and a sworn financial adviser, and is valid for 1 year from approval. The cost card amount is the total cost plus 15%. For a reimbursed product priced by cost card for the first time, the price may not exceed by more than 10% the cost card amount of the highest-priced identical product on the list that is marketed, reimbursed and not used as a source. Products whose price cannot be determined by any method are priced by the Price Evaluation Commission.

How are prices updated each year?

An Actual Source Price review is carried out every year for products on the price list, based on prices valid on 1 July of that calendar year. Applications are mandatory during the period for products whose Actual Source Price has changed; in 2026 this obligation covers all products except domestically manufactured non-reimbursed products and non-reimbursed traditional herbal medicinal products. Under the general calendar in the Pricing Guideline, applications are accepted in two windows (5–31 August and 23 November–6 December) and the final list is published on 21 December. TİTCK announced a separate calendar for 2026: the first application window closed on 23 October; the second window, for biosimilars, imported generics, reimbursed generics whose reference product is on the price list and non-reimbursed generics, runs from 1 to 21 December 2026; the final list will be published on 15 January 2027. For increase requests, up to 50% of the current company selling price is assessed if the source country has not changed, and up to 20% if it has. For imported products that do not apply, the Ministry determines the price ex officio and applies only decreases; for domestically manufactured products without a cost card, the current price is entered on the list as the cost card amount. We prepare and follow up your period applications on your behalf.

What is the Fixed Euro Rate and when does it change?

The euro rate used in pricing is calculated by multiplying the annual average of the previous year’s daily Central Bank of the Republic of Türkiye euro selling rates by the adjustment coefficient in the Decree. The Price Evaluation Commission announces it within the first 45 days of each year. An increase takes effect 5 days after the announcement and a decrease 45 days after. Prices on the list are updated without an application.

How is a price application made?

Applications are made in TİTCK’s Medicine Pricing and Market Analysis System (İFPAS), opened via “Yeni Fiyat” (New Price) in the Electronic Application and Process Management System (EBS-ESY). The applicant selects the application document type (e.g. first-time price evaluation and listing, a price list change requiring re-evaluation, a voluntary price decrease or an export price certificate) and completes the electronic price declaration form; product data are filled in automatically from the marketing authorisation records. The application PDF is signed electronically and uploaded as the cover letter, supporting documents are attached and, where a fee applies, the application reaches the Agency once the fee is paid. Its status (sent to the Agency, incomplete/incorrect, rejected, approved) is tracked in İFPAS, and incomplete applications are corrected and resubmitted for re-evaluation. Where necessary, the system converts the application into a Price Evaluation Committee application, which is also the route for differentiated price requests under the Alternative Reimbursement Commission (AGÖK). We prepare and follow up your applications in İFPAS on your behalf.

Which documents are required, and how long does it take?

A signed cover letter is mandatory for every application. In İFPAS, a price declaration document is mandatory for first-time price applications and price list changes requiring re-evaluation, and a cost card is added where required. The price declaration document must be apostilled or consular-legalised and state the price validity date; it is valid for 1 year from that date, and prices in currencies other than the euro are stated in their own currency. Where prices from countries published by the Ministry are submitted, the prices of identical products in the 10 countries with the lowest ex-factory prices (or in as many countries as can be accessed) and these countries’ 2025 market shares must be provided; for price declarations already prepared, an additional price declaration containing the 10-country prices is required. Applications other than period and Committee applications are concluded within 45 days at the latest. The price list is announced every Friday and takes effect the following Tuesday. Application documents must be kept for 10 years.

Get in touch

Let’s plan the next steps for your product

Tell us about your product, its current regulatory and pricing status and your target timeline, and we will get back to you promptly.